BlackRock Technology and Private Equity Term Trust (BTX) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential
Current Price
$6.55
Price Target
—
Target Range
— — —
Analyst Rating
—
Forward P/E—
Trailing P/E38.6x
Forward PEG—
Implied Growth—
Median Target—
Analyst Spread—
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$—
—
Consensus
$—
—
Bull Case
$—
—
BTX Price Target Analysis
Updated March 4, 2026As of March 4, 2026, BlackRock Technology and Private Equity Term Trust (BTX) has a Wall Street consensus price target of N/A, based on estimates from 0 covering analysts. The company has a market capitalization of $765M.
Analyst price targets range from a low of N/A to a high of N/A.
The current analyst consensus rating is N/A, with 0 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. The bearish sentiment suggests caution about the stock at current levels.
From a valuation perspective, BTX trades at a trailing P/E of 38.6x.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+92.5%
Avg Forward P/E24.5x
Peers with Coverage5 / 8
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
| BTXBlackRock Technology and Private Equity Term Trust | $765M | $6.55 | — | — | — | — | — |
 RPRXRoyalty Pharma plc | $7.1B | $47.26 | $49.40 | +4.5% | Buy | 9.7x | 11 |
 LGNDLigand Pharmaceuticals Incorporated | $4.0B | $202.09 | $248.00 | +22.7% | Buy | 23.8x | 16 |
 INVAInnoviva, Inc. | $1.7B | $22.25 | $32.50 | +46.1% | Buy | 11.3x | 10 |
 XOMAPXOMA Corporation | $321M | $26.06 | — | — | Buy | 39.1x | 9 |
 XOMAXOMA Royalty Corp. | $305M | $25.54 | $68.25 | +167.2% | Buy | 38.3x | 10 |
 CBUSCibus, Inc. | $106M | $3.57 | $11.50 | +222.1% | Buy | — | 3 |
 CDTCDT Equity Inc. | $30M | $0.60 | — | — | — | — | — |
Upside Potential Comparison
CBUSXOMAINVALGNDRPRXSee BTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BTX Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare BTX vs AGIO
See how BTX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
What is the BTX stock price target for 2026?
The consensus price target for BTX is $N/A, close to the current price of $6.555 (N/A% implied move). Based on 0 analyst estimates, the stock appears fairly valued near current levels.
Is BTX a buy, sell, or hold?
BTX has a consensus rating of "N/A" based on 0 Wall Street analysts. The rating breakdown is mixed, with 0 Hold ratings making up the largest segment. The consensus 12-month price target of $N/A implies N/A% upside from current levels.
Is BTX stock overvalued or undervalued?
BTX's current price is $6.555 with a consensus target of $N/A (N/A% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
How high can BTX stock go?
The most bullish Wall Street analyst has a price target of $N/A for BTX, while the most conservative target is $N/A. The consensus of $N/A represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover BTX stock?
BTX is lightly followed, with 0 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 0 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the BTX stock forecast?
The 12-month BTX stock forecast based on 0 Wall Street analysts shows a consensus price target of $N/A, with estimates ranging from $N/A (bear case) to $N/A (bull case). The median consensus rating is "N/A".
Should I buy BTX stock?
BTX appears fairly valued according to analysts, with a "N/A" rating and minimal upside to the $N/A target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do BTX price targets vary so much?
BTX analyst price targets range from $N/A to $N/A, a NaN% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $N/A consensus represents the middle ground.